Evidently, the TauRx (LMTX) P3 trial is not producing BTD type results or it would have likely been halted and approved after 6 months. Their 1st generation drug (Rember) was shown to only slow the progression of the disease (80%)...good, but not great. There were also unpleasant side effects, including nausea and diarrhea...and it also turns one's urine blue (yikes!). LMTX (their 2nd gen drug) was designed to mitigate the side effects, but its efficacy will likely show similar results.
P3 trial of LMTX to be completed in Q3.
From all indications thus far, it seems the results of 2-73 are much better.
News 
Market Data 
Discover 
AI
